What's Hot

    Scotland cause major upset in their Euro 2024 qualifier by defeating Spain 2-0

    March 28, 2023

    Healthcare Revolution: Medical Tourism and the American Dream

    March 28, 2023

    Kivu Consulting, Inc. announces strategic partnership with Microsoft

    March 28, 2023
    Iran DispatchIran Dispatch
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    Iran DispatchIran Dispatch
    Home » Early results of a study on an Alzheimer’s drug show promise
    Health

    Early results of a study on an Alzheimer’s drug show promise

    September 30, 2022
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    The shares of Biogen and other drugmakers researching Alzheimer’s disease surged Wednesday after Japan’s Eisai Co. Ltd.. reported its potential treatment appeared to slow the disease in a late-stage study. Lecanemab, the drugmaker’s treatment, reduced patients’ clinical decline by 27% after 18 months of infused treatment compared to placebos or fake drugs, according to AP reports.

    Early results of a study on an Alzheimer's drug show promiseThe results of Eisai’s global study of nearly 1,800 people with early-stage Alzheimer’s were announced late Tuesday. Mental decline and ability to do daily activities such as dressing and eating were measured using a scale. Eisai Co. Ltd. said it would present full research results at a conference in late November. The findings will also be published in a peer-reviewed medical journal.

    The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Biogen and Eisai will jointly promote the drug. Researchers usually caution against evaluating a study before full results are released. According to Mizuho Securities analyst Graig Suvannavejh, the initial findings are “quite robust” and support regulatory approval.

    According to the Alzheimer’s Association, the findings provide the highest hope so far for treating the disease’s underlying causes. Alzheimer’s disease affects some 6 million Americans and many more worldwide, gradually destroying parts of the brain that control memory, reasoning, communication, and basic daily functions.

    There is no known cure for Alzheimer’s disease. Researchers are still trying to understand what causes the disease, and long-standing treatments only manage symptoms. It has been nearly two decades since Biogen introduced a new Alzheimer’s drug. However, it has generally flopped after debuting at $56,000 annually, which Biogen later reduced. Due to weak evidence that the drug slows Alzheimer’s progression, doctors have been hesitant to prescribe it. Due to the drug’s high price and uncertain benefits, insurers have blocked or restricted coverage.

    Related Posts

    Exercise at certain times of the day increases longevity

    February 25, 2023

    Apple Watch may soon offer no-prick glucose monitoring

    February 24, 2023

    African leaders commit to ending AIDS among children by 2030

    February 2, 2023

    Feds say Florida nursing schools sold 7,600 fake diplomas

    January 28, 2023
    Latest News

    Scotland cause major upset in their Euro 2024 qualifier by defeating Spain 2-0

    March 28, 2023

    Kolkata is now served daily by Etihad Airways

    March 27, 2023

    With Trust International acquisition, Edge strengthens defence and technology portfolios

    March 27, 2023

    Indian space program places 36 satellites in their intended orbits

    March 27, 2023

    The third largest fish producer in the world, India accounts for 8 percent of global production

    March 25, 2023

    Canadian legislature laughs after Biden accidentally applauds China

    March 25, 2023

    First A380 service to Bali to be launched by Emirates

    March 24, 2023

    An oasis of tranquility for the diverse Abu Dhabi community – Abrahamic Family House

    March 24, 2023
    © 2022 Iran Dispatch | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.